Cargando…

Safety and Treatment Outcomes of Nivolumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Retrospective Multicenter Cohort Study

SIMPLE SUMMARY: Nivolumab is an anti-PD-1 monoclonal antibody that has been approved in the management of recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) with evidence of progression within 6 months of platinum-based chemotherapy. Most of the evidence regarding the use of nivoluma...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vasiliadou, Ifigenia, Breik, Omar, Baker, Holly, Leslie, Isla, Sim, Van Ren, Hegarty, Gemma, Michaelidou, Andriana, Nathan, Kannon, Hartley, Andrew, Good, James, Sanghera, Paul, Fong, Charles, Urbano, Teresa Guerrero, Lei, Mary, Petkar, Imran, Ferreira, Miguel Reis, Nutting, Chris, Wong, Kee Howe, Newbold, Kate, Harrington, Kevin, Bhide, Shree, Kong, Anthony
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003537/ https://www.ncbi.nlm.nih.gov/pubmed/33808781 http://dx.doi.org/10.3390/cancers13061413

Ejemplares similares

A multi-centre survey reveals variations in the standard treatments and treatment modifications for head and neck cancer patients during Covid-19 pandemic
por: Vasiliadou, Ifigenia, et al.
Publicado: (2021)

Practice patterns for the radical treatment of nasopharyngeal cancer by head and neck oncologists in the United Kingdom
por: Petkar, Imran, et al.
Publicado: (2018)

The impact of restricted length of treatment field and anthropometric factors on selection of head and neck cancer patients for treatment on the MR-Linac
por: Ng-Cheng-Hin, Brian, et al.
Publicado: (2020)

Early-Stage Glottic Squamous Cell Carcinoma in the Era of Image-Guided Radiotherapy
por: Gupta, Amit, et al.
Publicado: (2021)

On-treatment immune prognostic score for patients with relapsed and/or metastatic head and neck squamous cell carcinoma treated with immunotherapy
por: Nenclares, Pablo, et al.
Publicado: (2021)

Sequential induction chemotherapy followed by radical chemo-radiation in the treatment of locoregionally advanced head-and-neck cancer
por: Bhide, S A, et al.
Publicado: (2008)

The role of macrophages in bone metastasis
por: Vasiliadou, Ifigenia, et al.
Publicado: (2013)

Delayed DNA double-strand break repair following platin-based chemotherapy predicts treatment response in head and neck squamous cell carcinoma
por: Bhide, S A, et al.
Publicado: (2016)

Evaluation of a multi-atlas CT synthesis approach for MRI-only radiotherapy treatment planning
por: Guerreiro, F., et al.
Publicado: (2017)

A phase II trial of induction chemotherapy and chemo-IMRT for head and neck squamous cell cancers at risk of bilateral nodal spread: the application of a bilateral superficial lobe parotid-sparing IMRT technique and treatment outcomes
por: Miah, A B, et al.
Publicado: (2015)

A prospective comparison of common toxicity criteria adverse events Version 3 and 4 in assessing oral mucositis for oral and oropharyngeal carcinoma
por: Hickman, M., et al.
Publicado: (2017)

Online adaptive radiotherapy for head and neck cancers on the MR linear Accelerator: Introducing a novel modified Adapt-to-Shape approach
por: Gupta, Amit, et al.
Publicado: (2021)

Recent advances in radiotherapy
por: Bhide, SA, et al.
Publicado: (2010)

Brain-Sparing Methods for IMRT of Head and Neck Cancer
por: Dunlop, Alex, et al.
Publicado: (2015)

Quality assurance of dysphagia-optimised intensity modulated radiotherapy treatment planning for head and neck cancer
por: Tyler, Justine, et al.
Publicado: (2021)

Plasma-Based microRNA Expression Analysis in Advanced Stage NSCLC Patients Treated with Nivolumab
por: Monastirioti, Alexia, et al.
Publicado: (2022)

Comparison of CT number calibration techniques for CBCT-based dose calculation
por: Dunlop, Alex, et al.
Publicado: (2015)

Recovery of Salivary Function: Contralateral Parotid-sparing Intensity-modulated Radiotherapy versus Bilateral Superficial Lobe Parotid-sparing Intensity-modulated Radiotherapy
por: Miah, A.B., et al.
Publicado: (2016)

Changes in multimodality functional imaging parameters early during chemoradiation predict treatment response in patients with locally advanced head and neck cancer
por: Wong, Kee H., et al.
Publicado: (2017)

DARS: a phase III randomised multicentre study of dysphagia- optimised intensity- modulated radiotherapy (Do-IMRT) versus standard intensity- modulated radiotherapy (S-IMRT) in head and neck cancer
por: Petkar, Imran, et al.
Publicado: (2016)

Treatment-Free Survival After Nivolumab vs Pembrolizumab vs Nivolumab-Ipilimumab for Advanced Melanoma
por: Gupta, Mehul, et al.
Publicado: (2023)

Looking a Gift Horse in the Mouth: Observations on NHS England's Interim Guidance on Pembrolizumab in Head and Neck Squamous Cell Cancer
por: Harrington, K.J., et al.
Publicado: (2020)

Nivolumab in the treatment of malignant melanoma: review of the literature
por: Mashima, Emi, et al.
Publicado: (2015)

Clinical utility of nivolumab in the treatment of advanced melanoma
por: Asmar, Ramsey, et al.
Publicado: (2016)

Nivolumab plus ipilimumab in the treatment of advanced melanoma
por: Tsai, Katy K., et al.
Publicado: (2015)

Progressive Multifocal Leukoencephalopathy after Treatment with Nivolumab
por: Martinot, Martin, et al.
Publicado: (2018)

Relapsed Myasthenia Gravis after Nivolumab Treatment
por: Mitsune, Ayumi, et al.
Publicado: (2018)

Autoimmune Diabetes and Thyroiditis Complicating Treatment with Nivolumab
por: Li, Li, et al.
Publicado: (2017)

Effective treatment of gallbladder neuroendocrine carcinoma with nivolumab
por: Kanda, Shinichiro, et al.
Publicado: (2023)

Inter-Observer Variation in Delineating the Pharyngeal Constrictor Muscle as Organ at Risk in Radiotherapy for Head and Neck Cancer
por: Petkar, Imran, et al.
Publicado: (2021)

Assessing Novel Drugs and Radiation Technology in the Chemoradiation of Oropharyngeal Cancer
por: Cristaudo, Agostino, et al.
Publicado: (2018)

First-line treatment of metastatic melanoma: role of nivolumab
por: Force, Jeremy, et al.
Publicado: (2017)

Predicting response to radical (chemo)radiotherapy with circulating HPV DNA in locally advanced head and neck squamous carcinoma
por: Lee, Jen Y, et al.
Publicado: (2017)

Prospective, longitudinal, multi-modal functional imaging for radical chemo-IMRT treatment of locally advanced head and neck cancer: the INSIGHT study
por: Welsh, Liam, et al.
Publicado: (2015)

Characterizing Heterogeneity within Head and Neck Lesions Using Cluster Analysis of Multi-Parametric MRI Data
por: Borri, Marco, et al.
Publicado: (2015)

Incorporating spatial dose metrics in machine learning-based normal tissue complication probability (NTCP) models of severe acute dysphagia resulting from head and neck radiotherapy
por: Dean, Jamie, et al.
Publicado: (2017)

Cost–Utility Analysis of Nivolumab in Adjuvant Treatment of Melanoma in France
por: Bregman, Bruno, et al.
Publicado: (2020)

Rapidly Progressive Acute Kidney Injury Associated with Nivolumab Treatment
por: Okawa, Sachi, et al.
Publicado: (2020)

Molecular correlates of response to nivolumab at baseline and on treatment in patients with RCC
por: Ross-Macdonald, Petra, et al.
Publicado: (2021)

Hypofractionated chemoradiation for head and cancer: Data from the PET NECK trial
por: Vreugdenhil, M., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_o4uhnhch386t5unak4t35cl8e7